News
The incretin-based therapies reduced mortality and hospitalization risk in individuals with heart failure with preserved ...
Cabozantinib plus atezolizumab improved progression-free survival in advanced prostate cancer after ARPI failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback